or Try an Advanced Search...

    Technical Analysis for BHC - Bausch Health Companies Inc.

    Grade Last Price % Change Price Change
    C 8.71 1.04% 0.09
    BHC closed up 1.04 percent on Friday, April 26, 2024, on 67 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 2
    *** please verify all earnings dates ***
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Up
    Historical BHC trend table...
    Date Alert Name Type % Chg
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    Up 3 Days in a Row Strength 0.00%
    Up 4 Days in a Row Strength 0.00%
    Oversold Stochastic Weakness 0.00%
    Stochastic Buy Signal Bullish 1.04%
    Outside Day Range Expansion 1.04%
    Wide Bands Range Expansion 1.04%
    Up 3 Days in a Row Strength 1.04%
    Oversold Stochastic Weakness 1.04%
    Boomer Buy Setup Bullish Swing Setup 1.75%
    Older End-of-Day Signals for BHC ...

       Recent Intraday Alerts

    Alert Time
    Up 2% about 16 hours ago
    60 Minute Opening Range Breakout about 17 hours ago
    Up 1% about 17 hours ago
    Rose Above Previous Day's High about 17 hours ago
    10 DMA Support about 18 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    BHC Chart by TradingView
    Basic chart:

    Profile

    Bausch Health Companies Inc. Description

    Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis and other dermatoses. It also offers a selection of aesthetic medical devices that address a variety of conditions, including facial wrinkles, acne, pigmentation conditions and laser hair removal, among others. The gastrointestinal (GI) segment offers products that treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, among others. Its eye health products are marketed in the following categories: Contact Lens, Pharmaceutical Products and Surgical.

    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Biotechnology Life Sciences Organ Systems Laser Eye Pharmaceutical Products Gastrointestinal S&P/Tsx 60 Index Medical Device Health Products Dermatology Psoriasis Gastroenterology Specialty Drugs Ulcerative Colitis Ulcer Colitis Atopic Dermatitis Acne Dermatitis Diarrhea Contact Lens Irritable Bowel Syndrome Generic Pharmaceutical Wrinkle Generic Pharmaceuticals Hair Removal Over The Counter Products Actinic Keratosis Keratosis

    Is BHC a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 25 Earnings Preview: Alignment Healthcare (ALHC) Q1 Earnings Expected to Decline
    Apr 24 Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for
    Apr 23 Bausch Health in 'Stronger Position' for Bausch + Lomb Distribution, RBC Says
    Apr 20 10 Best Healthcare Stocks to Buy Under $20
    Apr 11 Bausch Health to Announce First-Quarter 2024 Results on May 2
    Apr 11 Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
    Apr 11 Bausch wins US appeal to block Alvogen generic of diarrhea drug
    Apr 11 Bausch Health gains after appeals court affirms ruling in Norwich patent case (update)
    Apr 11 Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
    Apr 8 CANADA STOCKS-TSX ends flat as gold stocks drop, mood cautious ahead of rate decision
    See more BHC news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 11.46
    52 Week Low 5.5703
    Average Volume 3,123,604
    200-Day Moving Average 8.30
    50-Day Moving Average 9.26
    20-Day Moving Average 9.14
    10-Day Moving Average 8.62
    Average True Range 0.39
    RSI (14) 42.20
    ADX 28.67
    +DI 26.09
    -DI 16.62
    Chandelier Exit (Long, 3 ATRs) 10.28
    Chandelier Exit (Short, 3 ATRs) 9.54
    Upper Bollinger Bands 10.51
    Lower Bollinger Band 7.78
    Percent B (%b) 0.34
    BandWidth 29.80
    MACD Line -0.24
    MACD Signal Line -0.19
    MACD Histogram -0.057
    Fundamentals Value
    Market Cap 3.18 Billion
    Num Shares 365 Million
    EPS -2.65
    Price-to-Earnings (P/E) Ratio -3.29
    Price-to-Sales 0.35
    Price-to-Book 18.78
    PEG Ratio 0.63
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 9.08
    Resistance 3 (R3) 9.07 8.95 9.02
    Resistance 2 (R2) 8.95 8.85 8.95 9.00
    Resistance 1 (R1) 8.83 8.80 8.89 8.83 8.98
    Pivot Point 8.70 8.70 8.73 8.70 8.70
    Support 1 (S1) 8.58 8.61 8.64 8.59 8.44
    Support 2 (S2) 8.46 8.55 8.46 8.42
    Support 3 (S3) 8.34 8.46 8.40
    Support 4 (S4) 8.34